Renamed ProterixBio in April 2016 (fdba BioScale), the firm is focused on addressing the unmet need for tools to provide a real-time, biological assessment of a patient's disease stated. Organized around development of proprietary blood-based biomarker tests to manage chronic respiratory diseases, the objctive is to have ProterixBio's products enable health care providers better to manage the condition of their patients, avoid ingunnecessary hospitalizations and improving outcomes at reduced health-care costs.
